anti-EGFR antibody-drug conjugate ABBV-637

{
  "id": "MLC-T-ONC-010586",
  "term": "anti-EGFR antibody-drug conjugate ABBV-637",
  "field": "Oncology and biomedicine",
  "definition": "An antibody-drug conjugate (ADC) consisting of a monoclonal antibody directed against the epidermal growth factor receptor (EGFR) conjugated to an inhibitor of Bcl-extra large (Bcl-XL), with potential antineoplastic activity. Upon administration of anti-EGFR ADC ABBV-637, the monoclonal antibody moiety targets and binds to EGFR on tumor cell surfaces. Following receptor internalization, the Bcl-XL inhibitor is released, which targets, binds to and inhibits the activity of Bcl-XL. This restores apoptotic processes in EGFR-expressing tumor cells and inhibits the proliferation of EGFR-expressing tumor cells. EGFR, a receptor tyrosine kinase mutated in many tumor cell types, plays a key role in tumor cell proliferation and tumor vascularization.",
  "synonyms": [
    "anti-EGFR ADC ABBV-637",
    "anti-EGFR/Bcl-XL inhibitor ADC ABBV-637"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/anti-egfr-antibody-drug-conjugate-abbv-637/"
}